Differential MicroRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer

Human Mutation

Volumn 33, Issue 3, 2012, Pages 551-560

  Kanaan, Ziad ^a   Rai, Shesh N ^b   Eichenberger, M Robert ^a   Barnes, Christopher ^b   Dworkin, Amy M ^c   Weller, Clayton ^a   Cohen, Eric ^a   Roberts, Henry ^a   Keskey, Bobby ^a   Petras, Robert E ^d   Crawford, Nigel P S ^c   Galandiuk, Susan ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d Ameripath   (United States)

Author keywords

Cancer; Crohn disease; Dysplasia; IBD; MicroRNA; Ulcerative colitis

Indexed keywords

CYCLIN G; MESSENGER RNA; MESSENGER RNA 122; MESSENGER RNA 143; MESSENGER RNA 146BETA 5P; MESSENGER RNA 17; MESSENGER RNA 181 ALPHA; MESSENGER RNA LET 7E; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE REGULATION; CELL STRAIN HCT116; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DYSPLASIA; ENTERITIS; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NEOPLASM; PRIORITY JOURNAL; UPREGULATION;

CELL CYCLE; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; MICRORNAS;

EID: 84856848243     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22021     Document Type: Article

References (43)

1. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Autom Control 19:716-723.
2. Akao Y, Nakagawa Y, Naoe T. 2006. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29:903-906.
3. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. 2001. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854-862.
4. Broome U, Lofberg R, Veress B, Eriksson LS. 1995. Primary sclerosing cholangitis andulcerative colitis: evidence for increased neoplastic potential. Hepatology 22:1404-1408.
5. Bruwer M, Schmid KW, Senninger N, Schurmann G. 2002. Immunohistochemical expression of P53 and oncogenes in ulcerative colitis-associated colorectal carcinoma. World J Surg 26:390-396.
6. Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, Stevens AC, Rubin CE. 1992. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103:1602-1610.
7. Choi PM, Nugent FW, Schoetz DJ Jr., Silverman ML, Haggitt RC. 1993. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 105:418-424.
8. Collins PD, Mpofu C, Watson AJ, Rhodes JM. 2006. Strategies for detecting colon cancerand/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev CD000279.
9. Colliver DW, Crawford NP, Eichenberger MR, Zacharius W, Petras RE, Stromberg AJ, Galandiuk S. 2006. Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol 80:1-10.
10. Diggle PJ, Heagerty P, Liang KY, Zeger SL. 2002. Analysis of Longitudinal Data. 2nd edition. Oxford, England: Oxford University Press.
11. Ekbom A, Helmick C, Zack M, Adami HO. 1990. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336:357-359.
12. Feagins LA, Souza RF, Spechler SJ. 2009. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6:297-305.
13. Galiveti CR, Rozhdestvensky TS, Brosius J, Lehrach H, Konthur Z. 2010. Application of housekeeping npcRNAs for quantitative expression analysis of human transcriptome by real-time PCR. RNA 16:450-461.
14. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. 1994. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35:1590-1592.
15. Greenstein AJ. 2000. Cancer in inflammatory bowel disease. Mt Sinai J Med 67:227-240.
16. Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH Jr. 1981. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 48:2742-2745.
17. Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN. 1980. Malignancy in Crohn's disease. Gut 21:1024-1029.
18. Holzmann K, Klump B, Borchard F, Hsieh CJ, Kuhn A, Gaco V, Gregor M, Porschen R. 1998. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer 76:1-6.
19. Hugot JP, Zouali H, Lesage S, Thomas G. 1999. Etiology of the inflammatory bowel diseases. Int J Colorectal Dis 14:2-9.
20. Ingenuity Pathway Analysis Website (Help Manual). Accessed on March, 2010.
21. Judge TA, Lewis JD, Lichtenstein GR. 2002. Colonic dysplasia and cancer in inflammatory bowel disease. Gastrointest Endosc Clin N Am 12:495-523.
22. Jung SH. 2005. Sample size for FDR-control in microarray data analysis. Bioinformatics 21:3097-3104.
23. Kraus S, Arber N. 2009. Inflammation and colorectal cancer. Curr Opin Pharmacol 9:405-410.
24. Lakatos PL. 2006. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 12:6102-6108.
25. Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B. 1992. DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 102:1149-1154.
26. Loftus EV, Jr., Sandborn WJ. 2002. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 31:1-20.
27. Mestdagh P, Van VP, De WA, Muth D, Westermann F, Speleman F, Vandesompele J. 2009. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:R64.
28. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. 2003. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1:882-891.
29. Pradervand S, Weber J, Thomas J, Bueno M, Wirapati P, Lefort K, Dotto GP, Harshman K. 2009. Impact of normalization on miRNA microarray expression profiling. RNA 15:493-501.
30. Rhodes JM, Campbell BJ. 2002a. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 8:10-16.
31. Rhodes JM, Campbell BJ. 2002b. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 8:10-16.
32. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. 1983. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14:931-968.
33. TM Website (Help Manual), www.sabiosciences.com, Accessed on January, 2010.
34. Sato A, MacHinami R. 1999. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol Int 49:858-868.
35. Swartzman E, Shannon M, Lieu P, Chen SM, Mooney C, Wei E, Kuykendall J, Tan R, Settineri T, Egry L, Ruff D. 2010. Expanding applications of protein analysis using proximity ligation and qPCR. Methods 50:S23-S26.
36. Team RDC. 2005. R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing.
37. van der Lee JH, Wesseling J, Tanck MW, Offringa M. 2008. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. J Clin Epidemiol 61:324-330.
38. Viscido A, Bagnardi V, Sturniolo GC, Annese V, Frieri G, D'Arienzo A, Papi C, Riegler G, Corrao G, Caprilli R. 2001. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study. Dig Liver Dis 33:686-692.
39. Warren WD, Restrepo JE, Respess JC, Muller WH. 1963. The importance of hemodynamic studies in management of portal hypertension. Ann Surg 158:387-404.
40. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. 1973. Crohn's disease and cancer. N Engl J Med 289:1099-1103.
41. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, L'Abbe D, Yu Z, Shen SH. 2008. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 29:1710-1716.
42. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. 2006. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 12:2014-2024.
43. Yang L, Belaguli N, Berger DH. 2009. MicroRNA and colorectal cancer. World J Surg 33:638-646.